VJOncology is committed to improving our service to you

GU Cancers 2020 | Long OS with sipuleucel-T in mCRPC

VJOncology is committed to improving our service to you

Rana McKay

Rana McKay, MD, University of California, San Diego, CA, discusses overall survival (OS) among medicare patients recieving sipuleucel-T versus oral treatment for metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter